false
0001500198
0001500198
2024-02-13
2024-02-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): February 13, 2024
NeuroOne
Medical Technologies Corporation
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-40439 |
|
27-0863354 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
7599
Anagram Dr., Eden Prairie, MN 55344
(Address
of principal executive offices and zip code)
952-426-1383
(Registrant’s
telephone number including area code)
(Registrant’s
former name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common Stock, par value
$0.001 per share |
|
NMTC |
|
The Nasdaq Stock Market
LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
Growth Company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02 Results of Operations and Financial Condition.
On
February 13, 2024, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing its financial
results for the fiscal quarter ended December 31, 2023. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current
Report and is incorporated herein by reference.
In
accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or
otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings
under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation
language in such a filing, except as expressly set forth by specific reference in such a filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
| |
NEUROONE
MEDICAL TECHNOLOGIES CORPORATION |
| Dated: February 13, 2024 |
|
|
| |
By: |
/s/ David
Rosa |
| |
|
David Rosa |
| |
|
Chief Executive Officer |
2
Exhibit 99.1
NeuroOne® Reports First
Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
EDEN PRAIRIE, Minn., February 13, 2024 (GlobeNewswire)
-- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology
company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its
operating results for the first quarter fiscal year 2024 ended December 31, 2023.
First Quarter Fiscal Year 2024 and Recent
Business Updates
Financial Highlights:
| ● | Product revenue of $978,000 in Q1 2024, compared to $115,000 in
Q1 2023 |
| ● | Raised an additional $2.8 million using the ATM Offering in December 2023
and January 2024 |
Evo® sEEG:
| ● | Customer feedback remains positive as commercial launch expands with new
accounts |
| ● | Product exhibited at annual meeting of American Epilepsy Society (AES) in
December 2023 |
| ● | Completed full sales force training for Zimmer Biomet personnel in January
2024 |
OneRF™ Ablation System:
| ● | Received FDA 510(k) clearance in December 2023 to market the OneRF™
Ablation System for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures |
| ● | Placed component orders for OneRF™ Ablation System and began preparing
for pending product launch targeted in the second calendar quarter of 2024. |
| ● | Submitted an ICD-10-PCS hospital inpatient code application to the Centers
for Medicare and Medicaid Services (CMS) for the OneRF™ ablation procedure, to support accurate data collection and processing of
reimbursement claims by hospitals for the ablation procedure |
| ● | Presented posters on pre-clinical experience with OneRF™ Ablation System
at the Society for Neuroscience (SFN) and the AES annual meetings |
Drug Delivery Program:
| ● | Completed feasibility bench top testing and animal study demonstrating the
ability to deliver a therapy and provide recording capabilities using the sEEG drug delivery system. |
| ● | Continued discussions with potential strategic partners for use in clinical
studies and research |
Spinal Cord Stimulation Program:
| ● | Completed preclinical study of the first acute electrophysiology experiment
with NeuroOne’s lead in a sheep model |
| ● | Presented poster on pre-clinical experience with thin-film paddle leads at
North American Neuromodulation Society (NANS) in January 2024 |
Dave Rosa, CEO of NeuroOne, commented, “We are very pleased with
our results this quarter, highlighted by reaching a milestone achievement with FDA clearance of our OneRF™ Ablation System. This
represents the Company’s third product family to be cleared by the FDA and the Company’s first combination device that has
an indication for both recording electrical activity and ablation of nervous tissue. We are very excited to be the first to market this
novel technology in the United States and are preparing to initiate a limited commercial launch of the OneRF™ Ablation System in
the second quarter of calendar year 2024. We believe the OneRF™ Ablation System, with combination diagnostic and therapeutic functionality,
has the capability to create a paradigm shift in neurosurgical procedures. We are also pleased with the continued expansion of Zimmer
Biomet’s launch of the Evo SEEG electrode and the related increase in revenue over past quarters. We expect this trend to continue
with the expansion of additional centers. We believe the launch of the OneRF™ Ablation System will also have a positive impact on
Evo sEEG customer demand. Coupled with the progress on our drug delivery and spinal cord stimulation programs, we remain confident in
our strategic plan.”
Key Upcoming Milestones
Evo® sEEG:
| ● | Revenue expected to increase with the addition of new accounts by Zimmer
Biomet and with the introduction of the OneRF™ Ablation System |
OneRF™ Ablation System:
| ● | Initiate a limited commercial launch of the OneRF™ Ablation System
in the second quarter of calendar year 2024 |
| ● | Continue to explore additional applications and strategic partnership opportunities
for ablation in neurology and other attractive markets that could benefit from NeuroOne’s high-resolution, thin-film electrode technology |
Drug Delivery Program:
| ● | Refine prototype design and testing including preclinical in-vivo study |
| ● | Continue to identify potential strategic partners to utilize NeuroOne’s
drug delivery device in clinical studies and research |
Spinal Cord Stimulation Program:
| ● | Complete animal study to evaluate stimulation and battery performance using
the Company’s spinal cord stimulation electrode technology |
| ● | Complete cadaver lab with our Spinal Cord Stimulation Advisory Board to further
advance the development of the percutaneous implantation technique for NeuroOne’s thin-film paddle electrodes for spinal cord stimulation |
First Quarter Fiscal Year 2024 Financial
Results
Product revenue was $978,000 in
the first quarter of fiscal 2024, compared to product revenue of $115,000 in the first quarter of fiscal 2023. The Company had no
collaboration revenue in the first quarter of fiscal 2024, compared to collaboration revenue of $1,455,000 in the first quarter of fiscal
2023. Collaboration revenue in 2023 was derived from the Zimmer Development Agreement and represents the portion of the exclusivity and
milestone fee payments eligible for revenue recognition during the period.
Total operating expenses in the first quarter
of fiscal 2024 were $3.7 million, compared with $3.2 million in the first quarter of fiscal 2023. R&D expense in the
first quarter of fiscal 2024 was $1.5 million compared with $1.6 million in the same period of fiscal 2023. SG&A
expense in the first quarter of fiscal 2024 was $2.2 million compared with $1.7 million in the first quarter of fiscal
2023.
Net loss was $3.3 million for the
first quarter of fiscal 2024, compared to a net loss of $1.7 million in the first quarter of fiscal 2023.
In December 2023, the Company sold common
stock under the ATM Offering at an average price of $1.45 per share, from which the Company received net proceeds of $1.2 million.
As of December 31, 2023, the Company
had cash, cash equivalents, and short-term investments of $2.7 million, compared to $5.3 million as of September 30,
2023. The Company had working capital of $3.7 million as of December 31, 2023, compared to working capital of $5.5 million as of September
30, 2023.
The Company had no debt outstanding as of December
31, 2023.
Conference Call and Webcast
Tuesday, February 13, 2024 – 4:30 PM Eastern Time
Participant Dial-In:
888-506-0062 / +1 973-528-0011
Access Code:
540724
Live Webcast:
Join here.
Phone Replay:
877-481-4010/ +1 919-882-2331
Available through February 27, 2024
Webcast Replay:
Available for 12 months
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage
company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions
for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and
other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications
for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more
information, visit nmtc1.com.
Forward Looking Statements
This press release may include forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking
statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and
other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information
expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words
or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused
on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to
identify statements about the future. Forward–looking statements may include statements regarding the development of the Company’s
electrode technology program, applications for, or receipt of, regulatory clearance, the timing and extent of product launch and commercialization
of our technology, receipt of revenues from sale of the sEEG electrodes, timing and success of any clinical and pre-clinical testing,
the timing and extent of product launch and commercialization of our OneRF Ablation System, the potential capabilities of our OneRF Ablation
System, SCS and drug delivery programs, business strategy, market size, potential growth opportunities, future operations, future efficiencies,
and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement,
we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the
future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely
outside our control, including risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance
of our technology; whether due to supply chain disruptions, labor shortages or otherwise; risks that our technology will not perform as
expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital
requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain
coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related
to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth
potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that
we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described
under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements
speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements
for any reason, even if new information becomes available in the future.
Caution: Federal law restricts this device
to sale by or on the order of a physician.
Contact:
800-631-4030
ir@nmtc1.com
NeuroOne Medical Technologies Corporation
Balance Sheets
(unaudited)
| | |
As of
December 31,
2023 | | |
As of
September 30,
2023 | |
| | |
(unaudited) | | |
| |
| Assets | |
| | |
| |
| Current assets: | |
| | |
| |
| Cash and cash equivalents | |
$ | 2,680,985 | | |
$ | 5,322,493 | |
| Accounts receivable | |
| 543,399 | | |
| — | |
| Inventory | |
| 1,608,657 | | |
| 1,726,686 | |
| Prepaid expenses and other assets | |
| 259,966 | | |
| 263,746 | |
| Total current assets | |
| 5,093,007 | | |
| 7,312,925 | |
| Intangible assets, net | |
| 83,998 | | |
| 89,577 | |
| Right-of-use assets | |
| 140,198 | | |
| 169,059 | |
| Property and equipment, net | |
| 505,175 | | |
| 525,753 | |
| Total assets | |
$ | 5,822,378 | | |
$ | 8,097,314 | |
| | |
| | | |
| | |
| Liabilities and Stockholders’ Equity | |
| | | |
| | |
| Current liabilities: | |
| | | |
| | |
| Accounts payable | |
$ | 760,000 | | |
$ | 685,104 | |
| Accrued expenses and other liabilities | |
| 623,240 | | |
| 1,107,522 | |
| Total current liabilities | |
| 1,383,240 | | |
| 1,792,626 | |
| Operating lease liability, long term | |
| 20,982 | | |
| 55,284 | |
| Total liabilities | |
| 1,404,222 | | |
| 1,847,910 | |
| | |
| | | |
| | |
| Commitments and contingencies (Note 4) | |
| | | |
| | |
| | |
| | | |
| | |
| Stockholders’ equity: | |
| | | |
| | |
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding. | |
| — | | |
| — | |
| Common stock, $0.001 par value; 100,000,000 shares authorized; 24,831,090 and 23,928,945 shares issued and outstanding as of December 31, 2023 and September 30, 2023, respectively. | |
| 24,831 | | |
| 23,929 | |
| Additional paid–in capital | |
| 70,424,528 | | |
| 68,911,778 | |
| Accumulated deficit | |
| (66,031,203 | ) | |
| (62,686,303 | ) |
| Total stockholders’ equity | |
| 4,418,156 | | |
| 6,249,404 | |
| Total liabilities and stockholders’ equity | |
$ | 5,822,378 | | |
$ | 8,097,314 | |
NeuroOne Medical Technologies Corporation
Statements of Operations
(unaudited)
| | |
For the three months ended
December 31, | |
| | |
2023 | | |
2022 | |
| | |
| | |
| |
| Product revenue | |
$ | 977,649 | | |
$ | 114,579 | |
| Cost of product revenue | |
| 711,335 | | |
| 126,886 | |
| Product gross profit (loss) | |
| 266,314 | | |
| (12,307 | ) |
| | |
| | | |
| | |
| Collaborations revenue | |
| — | | |
| 1,455,188 | |
| | |
| | | |
| | |
| Operating expenses: | |
| | | |
| | |
| Selling, general and administrative | |
| 2,173,472 | | |
| 1,663,737 | |
| Research and development | |
| 1,483,317 | | |
| 1,563,496 | |
| Total operating expenses | |
| 3,656,789 | | |
| 3,227,233 | |
| Loss from operations | |
| (3,390,475 | ) | |
| (1,784,352 | ) |
| Other income | |
| 45,575 | | |
| 51,583 | |
| Loss before income taxes | |
| (3,344,900 | ) | |
| (1,732,769 | ) |
| Provision for income taxes | |
| — | | |
| — | |
| Net loss | |
$ | (3,344,900 | ) | |
$ | (1,732,769 | ) |
| Net loss per share: | |
| | | |
| | |
| Basic and diluted | |
$ | (0.14 | ) | |
$ | (0.11 | ) |
| Number of shares used in per share calculations: | |
| | | |
| | |
| Basic and diluted | |
| 23,995,610 | | |
| 16,230,997 | |
6
v3.24.0.1
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
NeuroOne Medical Technol... (NASDAQ:NMTC)
Historical Stock Chart
From Apr 2024 to May 2024
NeuroOne Medical Technol... (NASDAQ:NMTC)
Historical Stock Chart
From May 2023 to May 2024
